Shots:

• The P-l trial will evaluate the safety- tolerability- and PK of ReS19-T for the treatment of AD. In preclinical studies- ReS19-T has shown to robustly restore synaptic plasticity with an acute response and improve inflammation and AD pathology over a longer treatment duration
• reMYND has a broad pipeline of novel programs in development- with a diabetes program scheduled to initiate human trials in mid-2021
• RES19-T is a novel approach addressing the AD at its root and restore cognition in patients by reducing the cellular damage associated with memory loss

 ­ Ref: Globe Newswire | Image: reMYND